- Home
- PTIX vs PMAX Comparison
PTIX vs PMAX Comparison
Compare PTIX & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- PMAX
- Stock Information
- Founded
- PTIX 1994
- PMAX 2019
- Country
- PTIX United States
- PMAX Hong Kong
- Employees
- PTIX N/A
- PMAX N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- PMAX
- Sector
- PTIX Health Care
- PMAX
- Exchange
- PTIX Nasdaq
- PMAX Nasdaq
- Market Cap
- PTIX 6.3M
- PMAX 6.9M
- IPO Year
- PTIX 2016
- PMAX 2024
- Fundamental
- Price
- PTIX $2.76
- PMAX $2.68
- Analyst Decision
- PTIX
- PMAX
- Analyst Count
- PTIX 0
- PMAX 0
- Target Price
- PTIX N/A
- PMAX N/A
- AVG Volume (30 Days)
- PTIX 73.5K
- PMAX 1.5M
- Earning Date
- PTIX 11-13-2025
- PMAX 09-23-2025
- Dividend Yield
- PTIX N/A
- PMAX N/A
- EPS Growth
- PTIX N/A
- PMAX N/A
- EPS
- PTIX N/A
- PMAX N/A
- Revenue
- PTIX N/A
- PMAX $4,799,100.00
- Revenue This Year
- PTIX N/A
- PMAX N/A
- Revenue Next Year
- PTIX N/A
- PMAX N/A
- P/E Ratio
- PTIX N/A
- PMAX N/A
- Revenue Growth
- PTIX N/A
- PMAX N/A
- 52 Week Low
- PTIX $2.25
- PMAX $1.87
- 52 Week High
- PTIX $15.26
- PMAX $30.56
- Technical
- Relative Strength Index (RSI)
- PTIX 35.75
- PMAX 61.78
- Support Level
- PTIX $2.85
- PMAX $2.52
- Resistance Level
- PTIX $3.19
- PMAX $3.03
- Average True Range (ATR)
- PTIX 0.23
- PMAX 0.46
- MACD
- PTIX -0.04
- PMAX -0.08
- Stochastic Oscillator
- PTIX 5.61
- PMAX 8.60
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.